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Neuronal dysfunction and synaptic loss are major hallmarks of Alzheimer’s Disease (AD) 
which correlate with symptom severity. Impairment of the GABAergic inhibitory interneurons, 
which form around 20% of the total neuronal network, may be an early event contributing to 
neuronal circuit dysfunction in neurodegenerative diseases. This study examined the 
expression of two of the main classes of inhibitory interneuron, parvalbumin (PV) and 
somatostatin (SST) interneurons in the temporal cortex and hippocampus of AD and control 
cases, using immunohistochemistry. We report significant regional variation in the number of 
PV and SST interneurons with a higher number identified per mm2 in the temporal cortex 
compared to the hippocampus. Fewer SST+ interneurons, but not PV+ interneurons, were 
identified per mm2 in the temporal cortex of AD cases compared to control subjects. Our 
results support regional neuroanatomical effects on selective interneuron classes in AD, and 
suggest that impairment of the interneuronal circuit may contribute to neuronal dysfunction 
and cognitive decline in AD.  
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Introduction  1 
Neuronal dysfunction and synaptic loss are key features of Alzheimer’s Disease (AD) which 2 
correlate with symptom severity 1. Pyramidal neurons have been the main focus of study in 3 
relation to AD pathology 2, with cholinesterase inhibitors commonly used for symptomatic 4 
relief in AD. However, interneurons are also essential to the normal functioning of the 5 
neuronal network. Forming around 20% of the total neuronal network 3, most interneurons 6 
are γ-aminobutyric acid (GABA)ergic and inhibitory, also acting as a source of neuropeptides 7 
that help to regulate cortical function 4.  8 
There are three main classes of inhibitory interneuron with calcium-binding proteins and 9 
neuropeptides used to distinguish between them. The different types of interneuron provide 10 
GABA, a major inhibitory neurotransmitter, to different subcellular places with the most 11 
common class of cortical interneurons, being the calcium-binding protein parvalbumin (PV) 12 
expressing interneurons. These cells comprise of the chandelier cells which innervate the 13 
axon initial segment, basket cells that target the soma of excitatory cells, and trans-laminar 14 
interneurons 5. These interneurons are responsible for their fast-spiking activity and precise 15 
inhibitory control of pyramidal cell output 6. Somatostatin (SST) expressing interneurons, the 16 
Martinotti and non-Martinotti cells, fire more randomly and gradually to stimulus targeting 17 
dendrites of excitatory neurons 7. SST+ cells release GABA that acts on a wide array of 18 
GABA receptors (GABAR), alongside fast synaptic GABAAR, the slower more persistent 19 
metabotropic GABABRs become activated on pyramidal cells silencing connections between 20 
these excitatory cells 8. Furthermore it has been proposed that the GABA released from SST 21 
cells affects the connectivity between excitatory neurons, regardless of whether these 22 
excitatory neurons are synaptically connected with SST neurons 9. 23 
The third class of interneurons express the serotonin receptor 5HT3aR as well as expressing 24 
vasoactive intestinal peptide (VIP) and are distinguishable for synapsing PV+ and SST+ 25 
interneurons 10.Typical VIP expressing interneurons are bipolar displaying continuous 26 
adapting firing properties 11. 27 
Cognitive symptoms associated with AD are the result of altered neural networks including 28 
abnormal oscillatory rhythmic activity and network hypersynchrony that can occur many 29 
years prior to clinical symptom onset 12-14. Studies have shown the involvement of 30 
interneurons in regulating these neural circuits and networks to be altered in AD, suggesting 31 
that interneuron dysfunction could play a role in neuronal network failure and cognitive 32 
dysfunction in AD 15. The Tg8CRND8 mouse model of AD exhibits spatial memory deficits 33 
and altered anxiety alongside a reduced number of interneurons. Treatment with α-34 
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melanocyte stimulating hormone (α-MSH) improved spatial memory and prevented the loss 35 
of SST+ interneurons, demonstrating its role in restoring GABAergic inhibition to improve 36 
cognition in this model 16. Similarly, in the  APP/PS1 mouse model of AD SST+ interneurons 37 
decrease with aging compared to control mice, while PV+ interneurons were increased 38 
suggesting a diverse interneuron population vulnerability that may be related to amyloid beta 39 
(Aβ) pathology in AD 17. 40 
Previous work has shown that the enzymes responsible for degrading Aβ are expressed in 41 
interneurons 18. The presence of endothelin-converting enzyme (ECE-2) and neprilysin in 42 
interneurons suggests the possibility that Aβ may have a role in the regulation of inhibition, 43 
acting as a neuropeptide important for interneuronal function 18. Additionally, γ-aminobutyric 44 
acid (GABA) receptors are altered in AD 19 with a varied pattern of GABAB receptor R1 45 
protein (GBR1) expression throughout the hippocampus of AD patients. An increased GBR1 46 
expression was identified in the CA4 and CA3/2 areas, yet was rapidly reduced in the CA1 47 
region with advanced AD pathology and progression of neurofibrillary tangles (NFT) prior to 48 
neuronal cell death 19. These GABA receptors have been shown to be involved in the 49 
inhibitory neurotransmission system that could contribute to neuronal resistance seen in the 50 
initial stages of disease pathology. Thus changes in the balance between inhibitory and 51 
excitatory neurotransmission are likely to contribute to AD development. The learning and 52 
memory deficits that correlated with the age-dependent decline in SST+ interneurons in the 53 
apoE4-KI mouse model of AD were rescued following the restoration of GABA signaling 54 
using pentobarbital, a GABAA receptor enhancer 5. Another mutated amyloid precursor 55 
protein (APP) familial mouse model of AD exhibited memory deficits and a reduction in 56 
GABA related proteins and GABAergic interneurons as early as 4 months 20. With APP 57 
known to play a role in GABAergic synaptic formations, by administrating diazepam and 58 
correcting the APP function an improvement in memory and also reduced Aβ accumulation 59 
was seen. Clearly, the GABAergic deficiency caused memory deficits and contributed to Aβ 60 
accumulation in this model 20. 61 
We have investigated changes in two of the main subclasses of inhibitory interneurons, the 62 
PV- and SST- expressing interneuron in temporal structures of AD and age-matched control 63 
brain using an immunohistochemistry approach. We hypothesized that inhibitory neurons are 64 
lost in areas of the brain typically affected by pathology in AD. 65 
Materials and Methods 66 
Human central nervous system tissue 67 
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All formalin fixed paraffin embedded (FFPE) lateral temporal cortex (Brodmann areas 21/22) 68 
and hippocampus tissue was obtained from the Sheffield Brain Tissue Bank (SBTB). The 69 
SBTB gave full ethical approval for the use of tissue in this study (ref. 08/MRE00/103+5) as a 70 
Research Tissue Bank approved by the Scotland Research Ethics Committee. A summary of 71 
the cohort used in the study is provided in Table 1. 72 
Immunohistochemistry 73 
Immunohistochemistry (IHC) was performed using a standard avidin-biotin complex-horse 74 
radish peroxidase (ABC-HRP) method, and visualized with diaminobenzidine (DAB) (Vector 75 
Laboratories, UK). Briefly, deparaffinised 5μm sections were rehydrated and endogenous 76 
peroxidase quenched by blocking the sections in 3% H2O2/methanol for 20 minutes at room 77 
temperature (RT). Following antigen retrieval (Table 2) sections were blocked in 1.5% normal 78 
serum for 30 minutes at RT. Sections were incubated in the relevant optimal antibody dilution, 79 
washed thoroughly in tris buffered saline (TBS, pH7.5) and incubated in 0.5% biotinylated 80 
secondary antibody for 30 minutes at RT. After thorough washing in TBS the sections were 81 
incubated in ABC-HRP for 30 minutes at RT before a final wash in TBS and incubation in the 82 
substrate DAB for 5 minutes at RT, sections were dehydrated, cleared in xylene and mounted 83 
for image analysis. Negative controls (omission of the primary antibody and isotype controls) 84 
were incubated in each run. Additional dual labelling was completed where SST stained 85 
sections (using a standard ABC-HRP method as earlier)  were incubated with the avidin-biotin 86 
blocking kit (Vector Laboratories, UK), and incubated overnight at 4°C with anti-PV, followed 87 
by the alkaline-phosphatase-conjugated ABC (Vectastain Elite kit, Vector Laboratories, UK), 88 
developed with alkaline phosphatase substrate (Vector Laboratories, UK; red) and 89 
counterstained with haematoxylin. Negative controls consisted of sections incubated in the 90 
absence of primary antibody. 91 
 92 
Quantification of antibody staining and statistical analysis 93 
Immunostained sections were imaged using either a Nikon Eclipse 80i microscope (Nikon UK, 94 
Kingston upon Thames) or digitally scanned under a 40x objective lens using a Nanozoomer 95 
XR (Hamamatsu, Photonics Ltd., Hertfordshire, UK). Scanned sections were stored as 96 
NanoZoomer Digital Pathology Image (.ndpi) files, viewed and exported using NDP.View 2.  97 
Quantification of PV-specific immunoreactivity within the temporal cortex was performed by 98 
capturing non-overlapping bright-field microscope images at x20 magnification in three 99 
contiguous belt transects covering the total cortical thickness (Supp Fig 1). Within the 100 
hippocampus, five non-contiguous images along the pyramidal layer were exported from the 101 
6 
 
scanned sections at x20 magnification in the CA1 region, and three images in the subiculum. 102 
Non-overlapping images were exported from the scanned sections at x20 magnification 103 
across the thickest region of the entorhinal cortex in two contiguous belt transects (Supp Fig 104 
2). PV immunopositive cells were manually counted in each region as well as the total 105 
percentage PV area immunoreactivity analysed in Analysis^D, (Olympus Biosystems, 106 
Watford, UK). 107 
SST+ cells were more infrequent than PV, and therefore quantification was performed solely 108 
by manual cell counts rather than using computer-aided image analysis. Within the temporal 109 
cortex, SST immunopositive cells were counted in the area of highest expression in six non-110 
overlapping images exported from the scanned sections at x20 magnification in a contiguous 111 
belt. Within the CA1 and enthorinal cortex the areas of highest expression within the 112 
hippocampus, SST immunopositive cells were counted in six random images exported from 113 
the scanned sections at x20 magnification in both the CA1 and entorhinal cortex regions.  114 
All statistical analyses were performed using IBM SPSS Statistic v24. For variation between 115 
neuroanatomical regions, Friedman’s Two-Way Analysis of Variance was used to compare 116 
immunoreactivity in the four brain regions (temporal cortex, hippocampus CA1, subiculum and 117 
entorhinal cortex) across the full cohort. Post hoc differences were assessed by Wilcoxon 118 
Signed Rank Test. Statistical comparisons of quantitative data between the control and AD 119 
cases was performed using Mann-Whitney U Tests.  120 
 121 
Results 122 
Somatostatin (SST) interneurons were reduced in the temporal cortex of AD patients 123 
SST immunoreactivity was discretely associated with the cytoplasm of neuronal cell bodies 124 
and immediate extending dendrites (Figures 1a&b), therefore for quantification total cell 125 
counts were used (Table 3). In addition, immunoreactivity was located predominantly at the 126 
grey matter/white matter border (Figures 1c&d). There was significant neuroanatomical 127 
regional variation in the number of SST+ interneurons (F=18.96 2df p=<0.001) with an 128 
increased number in the temporal cortex compared to CA1 (p=0.001) and entorhinal cortex 129 
(p=0.006). There was a slight increase in the number of SST+ cells in the entorhinal cortex 130 
compared to CA1 regions (p=0.025) (Figure 2a). Overall, there was a reduction (of 131 
approximately 30%) in the number of SST+ interneurons in the temporal cortex of AD patients 132 
compared to control cases (Mann-Whitney U test p=0.040), although this did not achieve 133 
statistical significance if corrected for multiple testing using the Bonferroni method (p=0.102). 134 
No significant differences in the number of SST+ interneurons were detected between the 135 
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entorhinal cortex or CA1 regions of the hippocampus of AD patients and control cases (Mann-136 
Whitney U test p=0.382, p=0.673 respectively (Figure 2b). 137 
Parvalbumin (PV) immunoreactivity of neuronal cell bodies was more pronounced in a 138 
band like pattern of the outer layers of the cortex 139 
PV immunoreactivity was detected in the cytoplasm of neuronal cell bodies and immediate 140 
extending dendrites (Figures 3a&b). For quantification both the total percentage area of PV 141 
immunoreactivity and total cell count were used (Table 3). Immunoreactivity appeared higher 142 
in the more outer cortical layers (I-IV) of the temporal and entorhinal cortex in a band like 143 
pattern (Figure 3c). Within the hippocampus the staining pattern varied greatly with PV 144 
immunoreactivity of cell bodies in CA1 being more sparsely distributed than in the temporal 145 
cortex (Figure 3d), while in the subiculum the immunoreactivity appeared in clusters (Figure 146 
3e). One of the AD cases showed very limited cytoplasmic cell body staining with 147 
immunoreactivity restricted to the surface of neurons in a beaded string like manner, 148 
suggesting a synaptic bouton labelling pattern (Figure 3f). 149 
There was a significant difference in PV immunoreactive area (F= 37.87 3df p=<0.001) and 150 
cell count (F= 32.50 3df p=<0.001) across all four brain regions investigated. The temporal 151 
cortex had the highest total PV immunoreactivity and cell count per mm2 compared to the 152 
other three areas of the hippocampus (CA1, subiculum, entorhinal cortex) (p=<0.001). Within 153 
the hippocampus PV immunoreactivity was significantly higher in the subiculum compared to 154 
CA1 (p=<0.001) and entorhinal cortex (p=0.001) (Figure 4a). There was no significant 155 
difference in PV immunoreactivity between the CA1 and entorhinal cortex (p=0.485) (Figure 156 
4a).  157 
For cell count, the temporal cortex had significantly more PV immunopositive neurons per mm2 158 
compared to the CA1 and entorhinal cortex (p=<0.001 (Figure 4b). In contrast, there was no 159 
significant difference in the number of PV positive neurons per mm2 in the subiculum 160 
compared to the temporal cortex (p=0.372), likely reflecting extensive case to case variation 161 
in the immunoreactive profile (Figure 4b), Within the hippocampus the subiculum contained 162 
significantly more PV immunoreactive cells per mm2 than  CA1 (p=<0.001) and entorhinal 163 
regions (p=0.004), with an increase number of PV positive cells per mm2 in the entorhinal 164 
regions compared to CA1 (p=0.044) (Figure 4b). 165 
Parvalbumin (PV) immunoreactivity was not altered in AD and did not colocalise with 166 
somatostatin (SST) immunoreactivity  167 
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There were no significant differences in total PV immunoreactive area or cell count per mm2 168 
between AD and control cases regardless of the brain region investigated (Supp Fig 3). 169 
Additionally no colocalisation of PV and SST immunoreactivity was present (Supp Fig 4). 170 
 171 
Discussion 172 
This study suggests a trend to a decrease in SST+ interneurons per mm2 in the temporal 173 
cortex of AD cases whilst, in contrast, no significant difference in PV+ interneurons per mm2 174 
was identified in AD cases compared to control subjects, in several brain area investigated. 175 
Overall there are significant differences in the number of PV+ and SST+ interneurons per 176 
mm2 across neocortical and hippocampal subregions within the temporal lobe, with more of 177 
both types of interneuron identified in the temporal cortex compared to hippocampal 178 
subfields.  179 
A major role of interneurons is to influence neuronal circuits by modulating the action of 180 
excitatory neurons. SST and PV expressing cells are subsets of GABAergic interneurons 9, 181 
each providing GABAergic input to specific subcellular domains at defined rates and times 6. 182 
The unique entity of each interneuron is shown by the lack of colocalisation between PV and 183 
SST expressing interneuron which is supported by other work identifying the non-184 
overlapping groups of interneurons 21-24. Alterations in the gene expression, neural activity 185 
and anatomy of SST+ interneurons have been identified in a number of psychiatric and 186 
neurological disease including schizophrenia, seizure disorders and epilepsy 9. In particular 187 
SST depletion in the cortex and hippocampus of AD patients has been connected to memory 188 
and learning impairment 25, 26. Similarly, SST interneuron decline has been identified in a 189 
number of AD animal models strongly correlating with memory and learning impairments 16, 190 
27-29. By restoring GABA receptor signalling with pentobarbitol following GABAergic 191 
interneuronal loss, memory and learning deficits were rescued in the apoE4-KI mice 5. Also, 192 
the use of the neuroprotective peptide α-MSH attenuated GABAergic interneuron loss and 193 
improved cognition in the TgCRND8 mouse model of AD 16.   194 
Repetitive activity in pyramidal neurons can drive SST+ interneurons into providing feedback 195 
inhibition 30, 31. Consequently, a decrease in SST+ interneurons in AD temporal cortex as seen 196 
in the current study, could act as a protective measure, enabling the continuing excitation of 197 
surviving pyramidal neurons to compensate for their progressive loss seen in the disease.  198 
Sub-regions of the temporal cortex have important roles in coordinating hippocampal 199 
functions, therefore the reduction in SST+ interneurons within the temporal cortex of AD 200 
patients could suggest a disruption in the overall cortico-hippocampal network and loss of 201 
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inhibition downstream causing over excitation of pyramidal neurons in the hippocampus 32. 202 
Ultimately this could lead to associated negative effects such as an increase in oxidative 203 
stress, DNA damage and dysregulation of intracellular calcium that could contribute to 204 
neuronal death associated with AD 33.  205 
Previous work has shown several hundred somatostatin labelled neurons in layer II/III of the 206 
temporal cortex 34 however, this work investigated three epilepsy cases aged 25-30 yrs, thus 207 
differing in both age and pathology of the subjects in the current study. SST decrease in the 208 
brain with increasing age 35; this is further heightened in AD 36-39. Remaining SST+ neuronal 209 
processes in AD are located in close proximity to neuritic plaques in the cingulate, frontal, 210 
temporal cortex 40 and hippocampus 41. An early reduction in SST+ interneurons in the olfactory 211 
cortex of an AβPP/PS1 double transgenic mouse model of AD 37 has since been shown in 212 
human AD post mortem tissue where SST also colocalised with amyloid-beta (Aβ) in the 213 
olfactory cortex 38. In contrast SST+ interneurons rarely colocalised with tau protein 38. In AD 214 
the accumulation of Aβ has been suggested to be caused by the impaired clearance of the 215 
protein 42. It may be speculated that a loss of SST+ interneurons in AD, as seen in this study 216 
and others, may lead to a loss in Aβ degrading enzymes, including endothelin-converting 217 
enzyme ECE-2 and therefore reduced Aβ metabolism and clearance 18 resulting in Aβ 218 
accumulation and induced cell death 43.  Through mass spectrometry studies the most 219 
pronounced peptide to bind to Aβ was the cyclic neuroendocrine peptide somatostatin-14 220 
(SST-14) 44 highlighting the likely importance of the role of SST interaction with Aβ surrounding 221 
AD pathology. 222 
There is conflicting literature as to the significance of PV+ interneurons in AD. Human post 223 
mortem brain studies have shown a loss of PV+ interneurons in areas known to be affected 224 
early in the disease, including the entorhinal cortex and hippocampus 45-47 as well as in the 225 
hippocampus of patients with dementia with Lewy bodies 48. However, in contrast, other 226 
human studies showed little variation in PV+ interneurons in AD subjects, similar to our 227 
current findings, suggesting PV+ interneurons are resistant to degeneration in AD 49-51.  228 
However, despite no changes, PV-expressing synaptic boutons were identified surrounding 229 
pyramidal neurons in the hippocampus of some AD patients. This could suggest that as 230 
neurons are lost in the hippocampus, an area involved in early AD pathology, an increasing 231 
lack of stimulus onto GABAergic interneurons occurs. Ultimately this lack of innervation 232 
could lead to PV translocating to axonal terminals to maintain calcium homeostasis and 233 
synaptic inhibition in the remaining pyramidal neurons, as the dysregulation of intracellular 234 
calcium homeostasis due to synaptic impairment has been previously identified as an 235 
initiating factor in AD 52. However, a further detailed quantification of these synaptic boutons 236 
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is required in a larger sample size to confirm this.  Therefore the overall loss of PV+  237 
interneurons may be delayed and not seen until later in the disease as suggested in an 238 
AβPP/PS1 double transgenic mouse model of AD 37 where the differential vulnerability 239 
among interneuron populations was possibly related to Aβ pathology 17. Parvalbumin 240 
immunoreactivity in the subiculum was localised to the parvopyramdial clusters in the current 241 
study which has previously shown to be areas immunopositive for depositions of amyloid-Bri, 242 
an amyloidogenic fragment associated with a stop codon mutation in the BRI gene 53. 243 
However, no difference in parvalbumin immunoreactivity in the parvopyramdial clusters was 244 
identified between controls and AD subjects in this study possibly reflecting the small sample 245 
size. 246 
Alternatively, neuronal loss in AD and resulting loss of excitable input may cause interneuron 247 
dysfunction, rather than degeneration, which could explain the translocation of PV to synaptic 248 
boutons 54, 55. This translocation of PV could cause detrimental changes in the protein’s 249 
function causing calcium dysregulation and impaired interneuron inhibition, increasing 250 
pyramidal neuron excitability and ultimately neuronal loss associated with the disease. 251 
Restoring the function of PV+ interneurons has been shown to restore inhibitory synaptic 252 
transmission, network activity and cognitive deficits in human amyloid precursor protein 253 
(hAPP) transgenic mice 56. 254 
Development of effective therapeutics for treating AD will come about through a better 255 
understanding of the mechanisms underlying neuronal dysfunction and loss in the disease. 256 
Our current findings, the first neuropathological study investigating PV and SST interneuron 257 
distribution throughout the temporal cortex and hippocampus of human AD patients compared 258 
to control subjects suggest interneuron changes in AD may be selective to specific interneuron 259 
populations and anatomical location. However, these conclusions are based on investigations 260 
carried out on only a small number of cases and two subclasses of interneuron. In order to 261 
better understand the significance and of interneurons in AD, a much larger study examining 262 
more cases and investigating the various interneuron populations across different anatomical 263 
regions in the human AD brain is warranted.  264 
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Figure legends 272 
Figure 1 Somatostatin immunoreactivity. Somatostatin immunoreactivity was associated 273 
with the cytoplasm of interneuronal cell bodies (a, black arrows) and immediate dendritic 274 
processes (b, blue arrows) throughout the temporal cortex and hippocampus. 275 
Immunoreactivity was primarily located at the grey matter / white matter border (c, low 276 
magnification, d high magnification).  Scale bar a 100µm, b 100µm, c 500µm, d 100µm. 277 
Figure 2 Quantification of somatostatin immunoreactivity. There was significantly higher 278 
number of somatostatin immunoreactive interneurons per mm2  in the temporal cortex 279 
compared to CA1 and entorhinal cortex across all cases (AD and controls) investigated in 280 
this study (a). There was a reduction in the number of somatostatin interneurons per mm2   in 281 
the temporal cortex of AD patients compared to control cases (b). No differences were seen 282 
in the number of somatostatin interneurons per mm2   between AD and control cases in the 283 
other areas investigated (CA1 and entorhinal cortex) (b). *P=<0.05, **P=<0.01 ***P=<0.001. 284 
Figure 3 Parvalbumin immunoreactivity. Temporal and entorhinal cortex showed a 285 
regular pattern of parvalbumin positive interneurons with cytoplasmic (black arrow) and 286 
dendritic immunoreactivity (blue arrow) (a lower magnification, b higher magnification). This 287 
pattern of staining appeared in a band like pattern concentrating in the outer layers (I-IV) of 288 
the cortex (c). Within the CA1 region the immunoreactivity was more dispersed with 289 
cytoplasmic (black arrow) and dendritic immunoreactivity (blue arrow) (d) and 290 
immunoreactivity in the subiculum appeared in clusters (e black arrows). A bead-string like 291 
pattern of immunoreactivity was present lining neuronal cell bodies of areas of AD 292 
hippocampus (circled) (f). Scale bar a 250µm, b 100µm, c 500µm, d 100µm, e 500µm, f 293 
50µm. 294 
Figure 4 Quantification of parvalbumin immunoreactivity. Parvalbumin positive cells 295 
were counted and expressed as the total number of positive cells per mm2 (a). There overall 296 
total percentage parvalbumin immunoreactivity was calculated per total area examined (b). 297 
*P=<0.05, **P=<0.01 ***P=<0.001.   298 
Supplementary Figure 1. An illustration of transect belt sampling in the temporal 299 
cortex. Non-overlapping images were taken across the cortical layers at X20 magnification 300 
in three contiguous belts. The number of images in each belt varied according to the 301 
thickness of the cortex. 302 
Supplementary Figure 2. An illustration of plot sampling and transect belt sampling in 303 
the hippocampus.  Five randomly distributed images were taken from the CA1 region (blue) 304 
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and three randomly distributed images from the subiculum (red). Non-overlapping images 305 
were taken across the entorhinal cortex in two contiguous belts (green).  306 
Supplementary Figure 3. Boxplots showing total parvalbumin percentage area in the 307 
temporal cortex (a), subiculum (b), CA1 (c), and entorhinal cortex (d) and total cell count in 308 
the temporal cortex (e), subiculum (f), CA1 (g), and entorhinal cortex (h) in Alzheimer’s 309 
disease compared to control cases. 310 
Supplementary Figure 4. Somatostatin and parvalbumin interneurons are distinct 311 
cells. (a) Dual immunoreactivity of somatostatin interneurons (brown cells, blue arrows) 312 
showed no colocalisation with parvalbumin interneurons (red cells, black arrows) lower 313 
magnification. (b) Parvalbumin+ interneurons, higher magnification, (c,d) somatostatin+ 314 
















74 (59-84) (5/4) 47 (5-75) 1. No neurological disease. Brain age-
related changes.  
2. Atypical pneumonia. Brain no 
abnormality. 
3. Sudden death, history of epilepsy. 
Brain no abnormality 
4. Guillan-Barre Syndrome, metastatic 
carcinosarcoma. Brain lacunar infarct.  
5. Subarachnoid haemorrhage. No 
neurodegenerative pathology.  
6. Pneumonia, carcinoma of the 
bladder. Brain - basal Ganglia 
calcification. 
7. Cardiac failure, liver failure, chronic 
hepatitis C. Brain age-related 
changes. 
8. Hepatocellular carcinoma, cirrhosis. 
Brain no significant abnormality. 







75 (59-93) (5/4) 62 (24-96) Alzheimer’s Disease  
 
Braak Stage 5 (n=4), Braak Stage 6 (n=5).  
 
Neuritic plaque staging according to 
CERAD, moderate neuritic plaques (n=3), 
severe neuritic plaques (n=6). 
 
Table 1. Age, sex, post mortem delay (PMD) and cause of death of SBTB brain donors. 317 
*Information not available for 10 individuals (6 controls, 4 AD) 318 
Key: SBTB, Sheffield Brain Tissue Bank; F, female; M, male319 
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Parvalbumin  Ca2+ binding 
protein  













Table 2. Antibody source and specificity  
Key: RT, room temperature; MW, microwave; TSC, trisodium citrate buffer pH 6.5; EDTA, 
Ethylenediamine Tetra-acetic Acid pH 8.0. 
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  Parvalbumin  Somatostatin  
 








Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Temporal cortex 
      
Control 29.68 (6.85) 28.04 (11.92) 8.87 (4.54) 7.26 (8.42) 2.07 (0.63) 2.05 (0.82) 
AD 26.41 (9.19) 21.84 (8.71) 9.30 (3.35) 8.18 (2.35) 1.49 (0.51) 1.43 (0.41) 
CA1 
      
Control 4.58 (5.40) 3.77 (4.72) 0.15 (0.20) 0.05 (0.19) 0.49 (0.60) 0.41 (1.23) 
AD 3.63 (4.69) 1.89 (7.55) 0.18 (0.17) 0.14 (0.28) 0.82 (0.37) 0.82 (0.62) 
Subiculum 
      
Control 21.78 (14.53) 17.30 (25.15) 1.80 (2.45) 0.63 (2.01)     
AD 25.15 (17.10) 15.72 (34.60) 0.76 (0.68) 0.44 (1.07)     
Entorhinal cortex 
      
Control 8.87 (3.53) 9.14 (4.32) 0.14 (0.08) 0.13 (0.14) 1.14 (0.56) 1.23 (1.23) 
AD 9.63 (8.00) 15.09 (14.99) 0.23 (0.35) 0.12 (0.24) 1.05 (0.83) 0.82 (1.03) 
Table 3. Quantification of Parvalbumin and Somatostatin staining 
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